Sociodemographic and clinical correlates of gabapentin receipt with and without opioids among a national cohort of patients with HIV

References

• Becker, W. C., Gordon, K., Edelman, E. J., Kerns, R. D., Crystal, S., Dziura, J. D., Fiellin, L. E., Gordon, A. J., Goulet, J. L., Justice, A. C., Fiellin, D. A. (2016). Trends in any and high-dose opioid analgesic receipt among aging patients with and without HIV. AIDS and Behavior, 20(3), 679–686. https://doi.org/10.1007/s10461-015-1197-5
   PubMed Web of Science ®Google Scholar
• Bonnet, U., Banger, M., Leweke, F. M., Maschke, M., Kowalski, T., & Gastpar, M. (1999). Treatment of alcohol withdrawal syndrome with gabapentin. Pharmacopsychiatry, 32(3), 107–109. https://doi.org/10.1055/s-2007-979203
   PubMed Web of Science ®Google Scholar
• Bush, K., Kivlahan, D. R., McDonell, M. B., Fihn, S. D., & Bradley, K. A. (1998). The AUDIT alcohol consumption questions (AUDIT-C): An effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol use disorders identification test. Archives of Internal Medicine, 158(16), 1789–1795. https://doi.org/10.1001/archinte.158.16.1789
   PubMed Web of Science ®Google Scholar
• Buttram, M. E., Kurtz, S. P., Cicero, T. J., & Havens, J. R. (2019). An ethnographic decision model of the initiation of gabapentin misuse among prescription and/or illicit opioid (mis)user. Drug and Alcohol Dependence, 204, 107554. https://doi.org/10.1016/j.drugalcdep.2019.107554
   PubMed Web of Science ®Google Scholar
• Buttram, M. E., Kurtz, S. P., Ellis, M. S., & Cicero, T. J. (2019). Gabapentin prescribed during substance abuse treatment: The perspective of treatment providers. Journal of Substance Abuse Treatment, 105, 1–4. https://doi.org/10.1016/j.jsat.2019.07.011
   PubMed Web of Science ®Google Scholar
• Cantrell, F. L., Mena, O., Gary, R. D., & McIntyre, I. M. (2015). An acute gabapentin fatality: A case report with postmortem concentrations. International Journal of Legal Medicine, 129(4), 771–775. https://doi.org/10.1007/s00414-015-1193-3
   PubMed Web of Science ®Google Scholar
• Dart, R. C., Bartelson, B. B., Severtson, S. G., Bau, G., & Green, J. L. (2017). Increasing abuse of gabapentin and pregabalin as reported to U.S. Poison centers 2006 through 2014. Drug and Alcohol Dependence, 171, e51. https://doi.org/10.1016/j.drugalcdep.2016.08.152
   Google Scholar
• Dowell, D., Haegerich, T., & Chou, R. (2016). CDC guideline for prescribing opioids for chronic pain--United States, 2016. MMWR. Recommendations and Reports, 65(1), 1–49. https://doi.org/10.15585/mmwr.rr6501e1
   PubMed Web of Science ®Google Scholar
• Edelman, E. J., Gordon, K., Becker, W. C., Goulet, J. L., Skanderson, M., Gaither, J. R., Braden, J. B., Gordon, A. J., Kerns, R. D., Justice, A. C., Fiellin, D. A. (2013). Receipt of opioid analgesics by HIV-infected and uninfected patients. Journal of General Internal Medicine, 28(1), 82–90. https://doi.org/10.1007/s11606-012-2189-z
   PubMed Web of Science ®Google Scholar
• Edelman, E. J., Li, Y., Barry, D., Brennan Braden, J., Crystal, S., Kerns, R. D., Gaither, J. R., Gordon, K. S., Manhapra, A., Merlin, J. S., Moore, B. A., Oldfield, B. J., Park, L. S., Rentsch, C. T., Skanderson, M., Williams, E. C., Justice, A. C., Tate, J. P., Becker, W. C., Marshall, B. D. L. (2020). Trajectories of self-reported opioid use among patients with HIV engaged in care: Results from a national cohort study. JAIDS Journal of Acquired Immune Deficiency Syndromes, 84(1), 26–36. https://doi.org/10.1097/QAI.0000000000002310
   PubMed Web of Science ®Google Scholar
• Fischer, J. H., Barr, A. N., Rogers, S. L., Fischer, P. A., & Trudeau, V. L. (1994). Lack of serious toxicity following gabapentin overdose. Neurology, 44(5), 982–982. https://doi.org/10.1212/wnl.44.5.982
   PubMed Web of Science ®Google Scholar
• Gomes, T., Juurlink, D. N., Antoniou, T., Mamdani, M. M., Paterson, J. M., & van den Brink, W. (2017). Gabapentin, opioids, and the risk of opioid-related death: A population-based nested case-control study. PLOS Medicine, 14(10), e1002396. https://doi.org/10.1371/journal.pmed.1002396
   PubMed Web of Science ®Google Scholar
• Goodman, C. W., & Brett, A. S. (2017). Gabapentin and pregabalin for pain - is increased prescribing a cause for concern? New England Journal of Medicine, 377(5), 411–414. https://doi.org/10.1056/NEJMp1704633
   PubMed Web of Science ®Google Scholar
• Goodman, C. W., & Brett, A. S. (2019). A clinical overview of off-label use of gabapentinoid drugs. JAMA Internal Medicine, 179(5), 695–701. https://doi.org/10.1001/jamainternmed.2019.0086
   PubMed Web of Science ®Google Scholar
• Green, K., Cooke O'Dowd, N., Watt, H., Majeed, A., & Pinder, R. J. (2019). Prescribing trends of gabapentin, pregabalin, and oxycodone: A secondary analysis of primary care prescribing patterns in england. BJGP Open, 3(3), bjgpopen19X101662. https://doi.org/10.3399/bjgpopen19X101662
   PubMedGoogle Scholar
• Harris, A. H., Bowe, T., Hagedorn, H., Nevedal, A., Finlay, A. K., Gidwani, R., Rosen, C., Kay, C., Christopher, M. (2016). Multifaceted academic detailing program to increase pharmacotherapy for alcohol use disorder: Interrupted time series evaluation of effectiveness. Addiction Science & Clinical Practice, 11(1), 15. https://doi.org/10.1186/s13722-016-0063-8
   PubMedGoogle Scholar
• Hart, L. G., Larson, E. H., & Lishner, D. M. (2005). Rural definitions for health policy and research. American Journal of Public Health, 95(7), 1149–1155. https://doi.org/10.2105/AJPH.2004.042432
   PubMed Web of Science ®Google Scholar
• Hewitt, D. J., McDonald, M., Portenoy, R. K., Rosenfeld, B., Passik, S., & Breitbart, W. (1997). Pain syndromes and etiologies in ambulatory AIDS patients. Pain, 70(2-3), 117–123. https://doi.org/10.1016/s0304-3959(96)03281-2
   PubMed Web of Science ®Google Scholar
• Johansen, M. E. (2018). Gabapentinoid use in the United States 2002 through 2015. JAMA Internal Medicine, 178(2), 292–294. https://doi.org/10.1001/jamainternmed.2017.7856
   PubMed Web of Science ®Google Scholar
• Justice, A. C., Dombrowski, E., Conigliaro, J., Fultz, S. L., Gibson, D., Madenwald, T., Goulet, J., Simberkoff, M., Butt, A. A., Rimland, D., Rodriguez-Barradas, M., Gilbert, C. L., Oursler, K. A., Brown, S., Leaf, D. A., Goetz, M., Bryant, K. (2006). Veterans Aging Cohort Study (VACS): Overview and description. Medical Care, 44(8 Suppl 2), S13–S24. https://doi.org/10.1097/01.mlr.0000223741.02074.66
   PubMed Web of Science ®Google Scholar
• Justice, A. C., Holmes, W., Gifford, A. L., Rabeneck, L., Zackin, R., Sinclair, G. (2001). Development and validation of a self-completed HIV symptom index. Journal of Clinical Epidemiology, 54(Suppl 1), S77–S90. https://doi.org/10.1016/s0895-4356(01)00449-8
   PubMed Web of Science ®Google Scholar
• Krcevski Skvarc, N., Morlion, B., Vowles, K. E., Bannister, K., Buchsner, E., Casale, R., Chenot, J-F., Chumbley, G., Drewes, A. M., Dom, G., Jutila, L., O'Brien, T., Pogatzi-Zahn, L., Rakusa, M., Suarez-Serrano, C., Tolle, T., Hauser, W. (2021). European clinical practice recommendations on opioids for chronic noncancer pain - part 2: Special situations. European Journal of Pain, 25(5), 969–985. https://doi.org/10.1002/ejp.1744
   PubMed Web of Science ®Google Scholar
• Kroenke, K., Spitzer, R. L., & Williams, J. B. (2001). The PHQ-9: Validity of a brief depression severity measure. Journal of General Internal Medicine, 16(9), 606–613. https://doi.org/10.1046/j.1525-1497.2001.016009606.x
   PubMed Web of Science ®Google Scholar
• Kruszewski, S. P., Paczynski, R. P., & Kahn, D. A. (2009). Gabapentin-induced delirium and dependence. Journal of Psychiatric Practice, 15(4), 314–319. https://doi.org/10.1097/01.pra.0000358318.73684.df
   PubMed Web of Science ®Google Scholar
• Lavigne, J. E., Heckler, C., Mathews, J. L., Palesh, O., Kirshner, J. J., Lord, R., Jacobs, A., Amos, E., Morrow, G. R., Mustian, K. (2012). A randomized, controlled, double-blinded clinical trial of gabapentin 300 versus 900 mg versus placebo for anxiety symptoms in breast cancer survivors. Breast Cancer Research and Treatment, 136(2), 479–486. https://doi.org/10.1007/s10549-012-2251-x
   PubMed Web of Science ®Google Scholar
• Mahase, E. (2020). Gabapentinoids: Has reclassification really solved the problem? BMJ, 368, m114. https://doi.org/10.1136/bmj.m114
   PubMedGoogle Scholar
• Mariottini, C., Kriikku, P., & Ojanpera, I. (2020). Concomitant drugs with buprenorphine user deaths. Drug Alcohol Depend, Epub Ahead of print.
   Google Scholar
• Markowitz, J. S., Finkenbine, R., Myrick, H., King, L., & Carson, W. H. (1997). Gabapentin abuse in a cocaine user: Implications for treatment? Journal of Clinical Psychopharmacology, 17(5), 423–424. https://doi.org/10.1097/00004714-199710000-00012
   PubMed Web of Science ®Google Scholar
• Meng, F. Y., Zhang, L. C., Liu, Y., Pan, L. H., Zhu, M., Li, C. L., Li, Y. W., Qian, W., Liang, R. (2014). Efficacy and safety of gabapentin for treatment of postherpetic neuralgia: A meta-analysis of randomized controlled trials. Minerva Anestesiologica, 80(5), 556–567.
   PubMed Web of Science ®Google Scholar
• Merlin, J. S., Bulls, H. W., Vucovich, L. A., Edelman, E. J., & Starrels, J. L. (2016). Pharmacologic and non-pharmacologic treatments for chronic pain in individuals with HIV: A systematic review. AIDS Care, 28(12), 1506–1515. https://doi.org/10.1080/09540121.2016.1191612
   PubMed Web of Science ®Google Scholar
• Merlin, J. S., Zinski, A., Norton, W. E., Ritchie, C. S., Saag, M. S., Mugavero, M. J., Treisman, G., Hooten, W. M. (2014). A conceptual framework for understanding chronic pain in patients with HIV. Pain Practice, 14(3), 207–216. https://doi.org/10.1111/papr.12052
   PubMed Web of Science ®Google Scholar
• Miaskowski, C., Penko, J. M., Guzman, D., Mattson, J. E., Bangsberg, D. R., & Kushel, M. B. (2011). Occurrence and characteristics of chronic pain in a community-based cohort of indigent adults living with HIV infection. The Journal of Pain, 12(9), 1004–1016. https://doi.org/10.1016/j.jpain.2011.04.002
   PubMed Web of Science ®Google Scholar
• Montastruc, F., Loo, S. Y., & Renoux, C. (2018). Trends in first gabapentin and pregabalin prescriptions in primary care in the United Kingdom, 1993–2017. JAMA, 320(20), 2149–2151. https://doi.org/10.1001/jama.2018.12358
   PubMed Web of Science ®Google Scholar
• Nunes, E. V. (2014). Gabapentin: A new addition to the armamentarium for alcohol dependence? JAMA Internal Medicine, 174(1), 78–79. https://doi.org/10.1001/jamainternmed.2013.11973
   PubMed Web of Science ®Google Scholar
• Peckham, A. M., Evoy, K. E., Covvey, J. R., Ochs, L., Fairman, K. A., & Sclar, D. A. (2018). Predictors of gabapentin overuse with or without concomitant opioids in a commercially insured U.S. population. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 38(4), 436–443. https://doi.org/10.1002/phar.2096
   Google Scholar
• Peckham, A. M., Fairman, K. A., & Sclar, D. A. (2017). Call for increased pharmacovigilance of gabapentin. BMJ, 359, j5456. https://doi.org/10.1136/bmj.j5456
   PubMedGoogle Scholar
• Peckham, A. M., Fairman, K. A., & Sclar, D. A. (2018a). All-cause and drug-related medical events associated with overuse of gabapentin and/or opioid medications: A retrospective cohort analysis of a commercially insured US population. Drug Safety, 41(2), 213–228. https://doi.org/10.1007/s40264-017-0595-1
   PubMed Web of Science ®Google Scholar
• Peckham, A. M., Fairman, K. A., & Sclar, D. A. (2018b). Policies to mitigate nonmedical use of prescription medications: How should emerging evidence of gabapentin misuse be addressed? Expert Opinion on Drug Safety, 17(5), 519–523. https://doi.org/10.1080/14740338.2017.1390081
   PubMed Web of Science ®Google Scholar
• Peckham, A. M., & Sclar, D. A. (2018). Need for international classification of gabapentin as a controlled substance. BMJ, 363, k4978. https://doi.org/10.1136/bmj.k4978
   PubMedGoogle Scholar
• Peckham, A. M., & Sclar, D. A. (2019). Quantifying gabapentin misuse with opioids. The Primary Care Companion For CNS Disorders, 21(2), https://doi.org/10.4088/PCC.18l02386
   Google Scholar
• Reccoppa, L., Malcolm, R., & Ware, M. (2004). Gabapentin abuse in inmates with prior history of cocaine dependence. American Journal on Addictions, 13(3), 321–323. https://doi.org/10.1080/10550490490460300
   PubMed Web of Science ®Google Scholar
• Reeves, R. R., & Ladner, M. E. (2014). Potentiation of the effect of buprenorphine/naloxone with gabapentin or quetiapine. American Journal of Psychiatry, 171(6), 691. https://doi.org/10.1176/appi.ajp.2014.13111526
   PubMed Web of Science ®Google Scholar
• Rentsch, C. T., Morford, K. L., Fiellin, D. A., Bryant, K. J., Justice, A. C., & Tate, J. P. (2020). Safety of gabapentin prescribed for any indication in a large clinical cohort of 571,718 US Veterans with and without alcohol use disorder. Alcoholism: Clinical and Experimental Research, 44(9), 1807–1815. https://doi.org/10.1111/acer.14408
   PubMed Web of Science ®Google Scholar
• Schifano, F. (2014). Misuse and abuse of pregabalin and gabapentin: Cause for concern? CNS Drugs, 28(6), 491–496. https://doi.org/10.1007/s40263-014-0164-4
   PubMed Web of Science ®Google Scholar
• Schifano, F., D'Offizi, S., Piccione, M., Corazza, O., Deluca, P., Davey, Z., Di Melchiorre, G., Di Furia, L., Farre, M., Flesland, L., Mannonen, M., Majava, A., Pagani, S., Peltoniemi, T., Siemann, H., Skutle, A., Torrens, M., Pezzolesi, C., van der Kreeft, P., Scherbaum, N. (2011). Is there a recreational misuse potential for pregabalin? Analysis of anecdotal online reports in comparison with related gabapentin and clonazepam data. Psychotherapy and Psychosomatics, 80(2), 118–122. https://doi.org/10.1159/000321079
   PubMed Web of Science ®Google Scholar
• Slavova, S., Miller, A., Bunn, T. L., White, J. R., Kirschke, D., Light, T., Christy, D., Thompson, G., Winecker, R. (2018). Prevalence of gabapentin in drug overdose postmortem toxicology testing results. Drug and Alcohol Dependence, 186, 80–85. https://doi.org/10.1016/j.drugalcdep.2018.01.018
   PubMed Web of Science ®Google Scholar
• Smith, R. V., Havens, J. R., & Walsh, S. L. (2016). Gabapentin misuse, abuse and diversion: A systematic review. Addiction, 111(7), 1160–1174. https://doi.org/10.1111/add.13324
   PubMed Web of Science ®Google Scholar
• Smith, R. V., Lofwall, M. R., & Havens, J. R. (2015). Abuse and diversion of gabapentin among nonmedical prescription opioid users in Appalachian Kentucky. American Journal of Psychiatry, 172(5), 487–488. https://doi.org/10.1176/appi.ajp.2014.14101272
   PubMed Web of Science ®Google Scholar
• Soumerai, S. B., & Avorn, J. (1990). Principles of educational outreach ('academic detailing') to improve clinical decision making. JAMA: The Journal of the American Medical Association, 263(4), 549–556. https://doi.org/10.1001/jama.1990.03440040088034
   PubMed Web of Science ®Google Scholar
• St Clair, C. O., Golub, N. I., Ma, Y., Song, J., Winiecki, S. K., & Menschik, D. L. (2020). Characteristics associated With U.S. outpatient opioid analgesic prescribing and gabapentinoid co-prescribing. American Journal of Preventive Medicine, 58(1), e11–e19. https://doi.org/10.1016/j.amepre.2019.08.029
   PubMed Web of Science ®Google Scholar
• Tate, J. P., Sterne, J. A. C., Justice, A. C., Veterans Aging Cohort, S., & the Antiretroviral Therapy Cohort, C. (2019). Albumin, white blood cell count, and body mass index improve discrimination of mortality in HIV-positive individuals. AIDS, 33(5), 903–912. https://doi.org/10.1097/QAD.0000000000002140
   PubMed Web of Science ®Google Scholar
• Torrance, N., Veluchamy, A., Zhou, Y., Fletcher, E. H., Moir, E., Hebert, H. L., Donnan, P. T., Watson, J., Colvin, L. A., Smith, B. H. (2020). Trends in gabapentinoid prescribing, co-prescribing of opioids and benzodiazepines, and associated deaths in Scotland. British Journal of Anaesthesia, 125(2), 159–167. https://doi.org/10.1016/j.bja.2020.05.017
   PubMed Web of Science ®Google Scholar
• U.S. Department of Veterans Affairs. (2021). VA HIV Care. https://www.hiv.va.gov/about-index.asp
   Google Scholar
• U.S. Food & Drug Administration. (2019). FDA in brief: FDA requires new warnings for gabapentinoids about risk of respiratory depression. https://www.fda.gov/news-events/fda-brief/fda-brief-fda-requires-new-warnings-gabapentinoids-about-risk-respiratory-depression
   Google Scholar
• Vickers Smith, R., Boland, E. M., Young, A. M., Lofwall, M. R., Quiroz, A., Staton, M., & Havens, J. R. (2018). A qualitative analysis of gabapentin misuse and diversion among people who use drugs in Appalachian Kentucky. Psychology of Addictive Behaviors, 32(1), 115–121. https://doi.org/10.1037/adb0000337
   PubMed Web of Science ®Google Scholar
• Wang, J., & Zhu, Y. (2017). Different doses of gabapentin formulations for postherpetic neuralgia: A systematical review and meta-analysis of randomized controlled trials. Journal of Dermatological Treatment, 28(1), 65–77. https://doi.org/10.3109/09546634.2016.1163315
   PubMed Web of Science ®Google Scholar
• Williams, E. C., McGinnis, K. A., Tate, J. P., Matson, T. E., Rubinsky, A. D., Bobb, J. F., Lapham, G., Edelman, E. J., Catz, S. L., Satre, D. D., Bryant, K. J., Marshall, B. D. L., Kraemer, K. L., Bensley, K. M., Richards, J. E., Skanderson, M., Justice, A. C., Fiellin, D. A., Bradley, K. A. (2019). HIV disease severity is sensitive to temporal changes in alcohol use: A national study of VA patients with HIV. JAIDS Journal of Acquired Immune Deficiency Syndromes, 81(4), 448–455. https://doi.org/10.1097/QAI.0000000000002049
   PubMed Web of Science ®Google Scholar